ArticleInfectious diseases and therapy2026
Glecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04903626 (A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents With Acute Hepatitis C Virus), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents With Acute Hepatitis C Virus (HCV) Infection
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of direct-acting antiviral regimens for acute HCV infection: a systematic review and meta-analysis.Virology journal · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn a phase 3b study, glecaprevir/pibrentasvir (G/P) for 8 weeks was well tolerated and effective in treatment-naive adults with acute hepatitis C virus (HCV) infection. Here we analyze the efficacy and safety of G/P in adults with acute HCV infection with a history of prior HCV infection.
methodsParticipants with acute HCV were stratified by presence of prior HCV infection. Efficacy was assessed in the intention-to-treat population (ITT; all patients receiving ≥ 1 G/P dose) and modified ITT virologic failure population, which excluded non-virologic failures (mITT-VF). Safety (adverse events [AEs] and laboratory values) was assessed, as well as viral kinetics.
resultsAmong 286 participants, 52 (18.2%) had ≥ 1 prior HCV infection and 234 (81.8%) did not. High-risk characteristics in those with prior infection versus those without: human immunodeficiency virus (HIV) coinfection, 92.3% versus 40.2%; unprotected male-male sexual activity, 78.8% versus 63.7%; and current/recent injection drug use, 23.1% versus 12.4%, respectively. In the ITT, SVR12 was 98.1% (95% confidence interval [CI] 89.9-99.7) in those with a prior infection and 95.7% (95% CI 92.3-97.7) in those without. There were no virologic failures (SVR12 = 100% in the mITT-VF). Rates of serious AEs (5.8% versus 3.0%) and treatment-related AEs (17.3% versus 15.4%) were similar in those with or without prior HCV infection.
conclusionsIndividuals with acute HCV infection with a history of prior HCV infection can be successfully treated with G/P. Risk of reinfection in high-risk populations, such as high-risk sexual activity or injection drug use, highlights the need for ongoing testing for reinfection along with subsequent treatment.
trial registrationClinicalTrials.gov identifier: NCT04903626.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.